Patient-Oriented Dosing (POD)

Phase 3Small molecule

Patient-Oriented Dosing (POD) is one of 37 small molecule programs targeting Opioid Use Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid Use DisorderActive, not recruiting

Opioid Use DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

21 2

Sovaldi

Gilead

Approved

1 3

Dolophine

HHikma Pharmaceuticals LLC

Approved

6 4

Cabenuva

GSK

Approved

—5

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

3 6

Oxycontin

PProtega

Approved

3 7

Lucemyra

BBioCorRx Pharmaceuticals Inc

Approved

2 8

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 9

Narcan

SScienture

Approved

2 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid Use Disorder1 trial

Pain Self-Management and Patient-Oriented Dosing for Pain and Retention in Office-based Addiction Treatment: a Randomized Trial

Active, not recruiting·EErin Winstanley·Approved·NCT06367387·273 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Patient-Oriented Dosing (POD). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Patient-Oriented Dosing (POD) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Patient-Oriented Dosing (POD). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Erin Winstanley company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EErin Winstanley

Patient-Oriented Dosing (POD)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid Use Disorder1 trial

References

Drug Info

Quick Facts

Related News